Mentions:
1: Siobhain McDonagh (Lab - Mitcham and Morden) with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS - Speech Link
A Bill to set a target for the number of glioblastoma patients who take part in clinical trials each year; to require training for medical oncologists to include training relating to brain cancers; to provide that any drug that has been licensed for use on tumours must be trialled on people with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS, including a requirement that each such team must include a medical oncologist; to require manufacturers of drugs licensed to treat tumours to make those drugs available in specified circumstances for clinical trials relating to brain tumours; to make provision about the application of funding caps on funding for multi-drug treatments for glioblastoma brain tumours; to make provision about the processes for funding of drugs intended for the treatment of glioblastoma; to make provision about the management of drug trial data, for the purpose of increasing the quality of data relating to glioblastoma patients; to make provision about reviewing the allocation of existing funding for brain tumour research by the National Institute for Health and Care Research; to make provision about the direct referral of patients by optometrists to accident and emergency departments for the purpose of diagnosing brain tumours; and for connected purposes.
Mentions:
1: Siobhain McDonagh (Lab - Mitcham and Morden) with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS - Speech Link
A Bill to set a target for the number of glioblastoma patients who take part in clinical trials each year; to require training for medical oncologists to include training relating to brain cancers; to provide that any drug that has been licensed for use on tumours must be trialled on people with brain tumours; to make provision in relation to neuro-oncology multidisciplinary teams in the NHS, including a requirement that each such team must include a medical oncologist; to require manufacturers of drugs licensed to treat tumours to make those drugs available in specified circumstances for clinical trials relating to brain tumours; and for connected purposes.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, following research from Cancer Research UK which found that brain, other central nervous system and intracranial tumours incidence rates have increased by almost two-fifths in the UK since the early 1990s, what steps they are taking to ensure that the funding spent on brain tumour research keeps pace with the increased incidence.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research, through the National Institute for Health Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.
The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission (TJBCM) through the NIHR. Since the 2018 announcement, the NIHR has committed £11.3 million across 17 projects. It is worth noting that all applications that were fundable in open competition, have been funded.
There is still funding available from the original £40 million announced in 2018. We are committed to funding high-quality brain cancer research, and we expect to spend more as new research progresses.
Brain tumours are a difficult research area with a relatively small research community. To increase the quality, diversity, and number of brain cancer research proposals, the NIHR is working with the TJBCM and the research community to develop research capacity in the brain cancer community. The NIHR continues to encourage and welcome more funding applications for research into brain tumours.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they have taken to improve access to new drugs for brain tumour patients.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR invests in the research delivery workforce, the facilities, and the capacity to support clinical trials into all disease areas, including brain tumours. The NIHR Clinical Research Facilities and Experimental Cancer Medicine Centres support the delivery of early phase trials, and the NIHR Clinical Research Network and Patient Recruitment Centres support delivery and participation in later phase clinical trials.
The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new medicines, including for brain tumours, should be routinely funded by the National Health Service based on an assessment of their costs and benefits. NICE is able to recommend medicines for use through the Cancer Drugs Fund, where there is too much uncertainty for NICE to recommend routine use. NICE works closely with the Medicines and Healthcare Products Regulatory Agency to ensure that its appraisal timelines are aligned with the regulatory process. NICE is currently evaluating a number of potential new medicines for brain tumours.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how much funding they have allocated for research into the (1) cause, and (2) treatment, of astrocytoma brain tumours in each of the past ten years; and to which organisations and projects and those funds were allocated.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group.
The NIHR funds and supports health, public health and social care research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with astrocytoma brain tumours.
The following table shows NIHR-funded research into astrocytoma brain tumours since 2013/14:
Award Title | Contractor | Start Date | End Date | Status | Total Award Budget |
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 [ID5104] | The University of Sheffield | 12/10/2023 | 12/03/2024 | Active | £70,000 |
A randomized, double-blind, parallel group, placebo-controlled trial of metformin in tuberous sclerosis complex. | University Hospitals Bristol and Weston NHS Foundation Trust | 1/8/2012 | 28/2/2017 | Closed | £239,665 |
Grand total | - | - | - | - | £309,665 |
The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. The NIHR welcomes funding applications for research into any aspect of human health, including astrocytoma brain tumours. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality.
It is worth noting that all applications that were fundable in open competition have been funded. The Department works closely with research funding partners such as Cancer Research UK and the Medical Research Council, who fund research into new scientific discoveries.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will review spending on (1) gliomas, and (2) astrocytoma cancer, to account for any increase in incidences.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR’s research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission through the NIHR. Brain tumours are a difficult research area with a relatively small research community, so we are taking actions to grow the field, such as workshops for researchers, and research training for clinicians. In addition to research programme spend on projects, NIHR research infrastructure supports brain tumour research studies, mainly in the National Health Service. Between 2018 and 2022, UK Research and Innovation, including the Medical Research Council, awarded £23.2 million in brain tumour research funding.
The Government is committed to improving the survival rates for all cancers. The latest publicly available figures showed improved survival rates across almost all types of cancer, including brain cancer, since 2010. Early diagnosis is key to improving survival rates, and the Department is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028.
The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Over 340,000 people received their first cancer treatment in the 12 months to January 2024.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to reduce the adverse disparity in survival rates for brain tumour patients compared to other cancers whose treatment attracts greater levels of funding.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR’s research expenditure for all cancers was £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group.
In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission through the NIHR. Brain tumours are a difficult research area with a relatively small research community, so we are taking actions to grow the field, such as workshops for researchers, and research training for clinicians. In addition to research programme spend on projects, NIHR research infrastructure supports brain tumour research studies, mainly in the National Health Service. Between 2018 and 2022, UK Research and Innovation, including the Medical Research Council, awarded £23.2 million in brain tumour research funding.
The Government is committed to improving the survival rates for all cancers. The latest publicly available figures showed improved survival rates across almost all types of cancer, including brain cancer, since 2010. Early diagnosis is key to improving survival rates, and the Department is working towards the NHS Long Term Plan ambition of diagnosing 75% of stageable cancers at stage 1 and 2 by 2028.
The Government is working jointly with NHS England on implementing the delivery plan for tackling the COVID-19 backlogs in elective care, and plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment activity. Over 340,000 people received their first cancer treatment in the 12 months to January 2024.
Asked by: Laurence Robertson (Conservative - Tewkesbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that NICE clinical guidelines on Brain tumours (primary) and brain metastases in over 16s reflects the latest data from clinical trials on (a) diagnosis and (b) management of patients.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidelines for the National Health Service on best practice based on an assessment of clinical and cost effectiveness. NICE keeps its guidelines under review and uses the best available evidence to develop its recommendations. Its surveillance programme proactively explores whether there is any new evidence to contradict, reinforce or clarify its guideline recommendations.
NICE’s guideline on brain tumours and brain metastases in people aged 16 years old or over was most recently updated in 2021 and makes recommendations on the management of grade IV gliomas. The NHS is expected to take NICE guidelines fully into account in ensuring that services meet the needs of their local populations.
In May 2018, the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission, through the National Institute for Health and Care Research. This includes funding for glioblastoma research.